Epidermal growth factor receptor gene copy number

Details Epidermal growth factor receptor gene copy number Epidermal growth factor receptor gene copy number

2006-03-30

2009-12-22

Yu, Misook (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S006120

Reexamination Certificate

active

07635570

ABSTRACT:
Methods of predicting whether an anti-epidermal growth factor receptor (“EGFr”)-specific binding agent treatment will be efficacious in treating cancer, and methods of treating patients with anti-EGFr-specific binding agents, are provided.

REFERENCES:
patent: 2004/0132097 (2004-07-01), Bacus et al.
patent: 0 712 863 (1996-05-01), None
patent: WO 2004/111273 (2004-12-01), None
patent: WO 2005/117553 (2005-12-01), None
patent: WO 2006/108627 (2006-10-01), None
patent: WO 2007/001868 (2007-01-01), None
Sridhar, Lancet Oncology, 2003, 4:397-406.
Humblet, Expert Opin Pharmacother, 2004, 1621-1633.
Hirsch et al, J Clin Oncol, 2003, 3798-3807.
Amann et al., “Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer,”Cancer Res., 65: 226-235 (2005).
Barber et al., “Somatic mutations ofEGFRin colorectal cancers and glioblastomas,”N. Engl. J. Med, 351:2883 (2004).
Eberhard et al., “Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib,”J. Clin. Oncol., 23:5900-5909 (2005).
Gandara et al., “Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?”J. Clin. Oncol., 23:5856-5858 (2005).
Hirsch et al., “Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer,”Curr. Opin. Oncol., 17:118-122 (2005).
Hirsch et al., “Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis,”J. Clin. Oncol., 21: 3798-3807 (2003).
Hirsch et al., “Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A southwest oncology group study,”J. Clin. Oncol., 23: 6838-6845 (2005).
Johns et al., “Novel monoclonal antibody specific for the DE2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene,”Int. J. Cancer; 98: 398-408 (2002).
Kobayashi et al., “EGFRmutation and resistance of non-small-cell lung cancer to gefitinib,”N. Engl. J. Med., 352:786-792 (2005).
Lynch et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,”N. Engl. J. Med., 350:2129-2139 (2004).
Lynch et al., “A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC),”J. of Clin. Oncol., 2004 ASCO Ann. Meeting Proc., 22(14S):7084 (2004).
McIntyre et al., “Panitumumab. Oncolytic-Anti-EGFR human monoclonal antibody,”Drugs of the Future, 29: 793-797 (2004).
Moroni et al., “Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study,”Lancet Oncol. 6: 279-286 (2005).
Paez et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,”Science, 304: 1497-1500 (2004).
Pao et al., “EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib,”PNAS, 101: 13306-13311 (2004).
Stephens et al., “Intragenic ERBB2 kinase mutations in tumours,”Nature, 431:525-526 (2004).
Takano et al., “Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer,”J. Clin. Oncol., 23: 6829-6837 (2005).
Vogel et al., “Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer,”J. Clin. Oncol. 20: 719-726 (2002).
Wang et at, “Prevalence of somatic alterations in the colorectal cancer cell genome,”PNAS, 99:3076-3080 (2002).
PCT Notification of the Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration mailed Oct. 17, 2006; International Search Report, and the Written Opinion of the International Searching Authority, in Application No. PCT/US2006/012267.
Mukohara et al., “Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations,”J. Natl. Cancer Inst., 97: 1185-1194 (2005).
PCT International Preliminary Report on Patentability and Written Opinion of the International Searching Authority, mailed Oct. 3, 2007, for International Application No. PCT/US2006/012267.
Allison, “Is personalized medicine finally arriving?”Nat. Biotech., 26: 509-517 (2008).
Amado et al., “Wild-type KRAS is required for Panitumumab efficacy in patients with metastatic colorectal cancer”Journal of Clinical Oncology, 26(10): 1626-1634 (2008).
Amler et al., “Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors,”Cold Spring Harbor Symp. Quant.Biol., 70: 483-488 (2005).
Baselga et al., “Determinants ofRASistance to anti-epidermal growth factor receptor agents,”J. Clin. Oncol., 26: 1582-1584 (2008).
Benvenuti et al., “Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies,”Cancer Res., 67: 2643-2648 (2007).
Finocchiaro et al., “EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer,”ASCO, 2007 ASCO Annual Meeting, Abstract No. 4021 (2007).
Hecht et al., “Panitumumab (pmab) efficacy in patients (pts) with metastatic colorectal cancer (mCRC) with low or undetectable levels of epidermal growth factor receptor (EGFr): Final efficacy andKRASanalyses,”ASCO, 2008 Gastrointestinal Cancers Symposium, Abtract No: 343 (2008).
Moroni et al. “Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer,” Letter to the Editor,Ann. Onc., 16: 1848-1849 (2005).
Moroni et al., “EGFR FISH in colorectal cancer: what is the current reality?”Lancet Oncol., 9: 402-403 (2008).
Moroni et al., “Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature,”Targ. Oncol., 3:127-130 (2008).
Pessino et al., “First-line sincgle-agent cetuximab in patients with advanced colorectal cancer,”Annals of Oncology, 19:711-716 (2008).
Sartore-Bianchi et al., “Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab,”J. Clin. Oncol., 25: 3238-3245 (2007).
Van Custem et al, “Open label phase III trial of Panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer,”Journal of Clinical Oncology, 25(13): 1658-1664 (2007).
Office Action Mailed Apr. 2, 2008 in U.S. Appl. No. 11/548,386.
“Response to Office Action Mailed Apr. 2, 2008,” filed on Oct. 2, 2008, in U.S. Appl. No. 11/548,386.
Office Action Mailed Apr. 11, 2008 in U.S. Appl. No. 10/600,129.
“Response to Office Action Mailed Apr. 11, 2008,” filed on Oct. 13, 2008, in U.S. Appl. No. 10/600,129.
Invitation to Respond to Written Opinion in Singapore Patent Application No. 200716407-2, mailed Oct. 15, 2008.

Affiliated with

Also associated with

Rating

Epidermal growth factor receptor gene copy number does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Epidermal growth factor receptor gene copy number, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Epidermal growth factor receptor gene copy number will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4073706